Published on
August 6, 2025
- 11:00 GMT
ReEngage Therapeutics Completes First Tranche of Bridge Round
Funding allows company to prepare for Phase 1b clinical trial HOUSTON, TX, UNITED STATES, August 6, 2025 /EINPresswire.com/ -- ReEngage Therapeutics, a pharmaceutical company pioneering epigenetics to treat cancer and other longevity-related diseases, …
Distribution channels:
Business & Economy, Companies
...
